Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding disorders related to factor VIII and von Willebrand factor deficiencies. It is used in both prophylactic and on‑demand treatment settings.

• Prevention of bleeding episodes in patients with severe hemophilia A.
• Treatment of acute bleeding episodes in hemophilia A.
• Management of von Willebrand disease, including surgery‑related bleeding.
• Peri‑operative support for patients undergoing invasive procedures.
• Long‑term prophylaxis to reduce the frequency of spontaneous bleeds.

Side effects of Haemate P may vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common

• Headache
• Fever or chills
• Nausea or vomiting
• Injection site reactions such as redness or swelling
• Mild hypertension

Serious

• Development of inhibitors (antibodies) against factor VIII
• Anaphylactic or severe allergic reactions
• Thromboembolic events
• Renal impairment in rare cases

When using Haemate P, certain precautions should be observed to ensure safety and efficacy.

• Assess for a history of inhibitors to factor VIII before initiating therapy.
• Monitor for signs of allergic reactions during and after infusion.
• Use caution in patients with cardiovascular disease or a history of thrombosis.
• Adjust dosing in patients with renal or hepatic impairment as clinically indicated.
• Ensure proper aseptic technique to prevent contamination of the injectable solution.
• Educate patients on recognizing symptoms of inhibitor development.

Haemate P may interact with other medications or substances that affect coagulation or immune response.

Avoid

• Concurrent use of other clotting factor concentrates without medical guidance.
• Administration of pro‑thrombotic agents in patients with a high risk of thrombosis.

Use with caution

• Immunosuppressive drugs that may alter inhibitor formation.
• Antifibrinolytic agents (e.g., tranexamic acid) when combined with factor replacement.
• Vaccines administered shortly before or after infusion, to monitor for immune reactions.
• Medications that affect renal function, requiring dose adjustments.